Released Nov 5, 2026, before the open
10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-070575
On November 5, 2026, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2019 |
|---|---|---|---|
| Revenue | $8.47M | $11.23M | — |
| Net Income | -$21.84M | -$32.17M | -$10.09M |
| EPS Diluted |
C4 Therapeutics, Inc. · CIK 1662579 · Engraved from SEC EDGAR
| -$0.16 |
| -$0.44 |
| -$8.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
C4 Therapeutics, Inc. issued a press release on November 5, 2026 announcing its financial results and business highlights for the quarter ended September 30, 2026.¶1¶2
Total revenue for the third quarter of 2026 was $8.5 million, compared to $11.2 million for the third quarter of 2025, and net loss was $21.8 million, or $0.16 per share.¶3
Cash, cash equivalents, and marketable securities were $274.7 million as of September 30, 2026, and the company expects them to fund its operating plan to the end of 2028.¶3
Enrollment in the Phase 2 MOMENTUM trial is on track to complete in the first quarter of 2027, with initial ORR data expected in the second half of 2027.¶4